Revance Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US7613301099
USD
3.65
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

0

Shareholding (Sep 2024)

FII

28.78%

Held by 109 FIIs

DII

22.84%

Held by 61 DIIs

Promoter

1.37%

How big is Revance Therapeutics, Inc.?

22-Jun-2025

As of Feb 07, Revance Therapeutics, Inc. has a market capitalization of 381.02 million and reported net sales of 247.01 million with a net profit of -180.81 million over the latest four quarters. Shareholder's funds are at -151.60 million, and total assets amount to 478.45 million.

As of Feb 07, Revance Therapeutics, Inc. has a market capitalization of 381.02 million, categorizing it as a Micro Cap company.<BR><BR>As of Feb 07, the sum of net sales for the latest four quarters is 247.01 million, while the sum of net profit for the same period is -180.81 million.<BR><BR>As of Dec 23, the reporting period shows shareholder's funds at -151.60 million and total assets amounting to 478.45 million.

Read More

What does Revance Therapeutics, Inc. do?

22-Jun-2025

Revance Therapeutics, Inc. is a biotechnology company specializing in aesthetic and therapeutic pharmaceuticals, with a market cap of $381.02 million and quarterly net sales of $60 million but a net loss of $38 million as of September 2024.

Overview:<BR>Revance Therapeutics, Inc. is a biotechnology company focused on aesthetic and therapeutic offerings within the pharmaceuticals industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Net Sales: 60 Million (Quarterly Results - Sep 2024)<BR>Net Profit: -38 Million (Quarterly Results - Sep 2024)<BR>Market cap: USD 381.02 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Dividend Yield: 84.25%<BR>Debt Equity: -1.62<BR>Return on Equity: 109.95%<BR>Price to Book: -2.34<BR><BR>Contact Details:<BR>Address: 1222 Demonbreun Street, Suite 1001, NASHVILLE TN : 37203<BR>Tel: ['1 510 7423400', '1 714 3253584']<BR>Fax: 1 302 6745266<BR>Website: http://www.revance.com/

Read More

Should I buy, sell or hold Revance Therapeutics, Inc.?

22-Jun-2025

Who are in the management team of Revance Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Revance Therapeutics, Inc. includes Mr. Angus Russell (Independent Chairman), Mr. Mark Foley (CEO), and several independent directors: Mr. Aubrey Rankin, Ms. Jill Beraud, Mr. Robert Byrnes, Mr. Julian Gangolli, and Dr. Phyllis Gardner. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Revance Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Angus Russell, Independent Chairman of the Board<BR>- Mr. Mark Foley, President, Chief Executive Officer, and Director<BR>- Mr. Aubrey Rankin, Director<BR>- Ms. Jill Beraud, Independent Director<BR>- Mr. Robert Byrnes, Independent Director<BR>- Mr. Julian Gangolli, Independent Director<BR>- Dr. Phyllis Gardner, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Sep 24

  • DEBTORS TURNOVER RATIO(HY) Lowest at 6.71%
  • CASH AND EQV(HY) Lowest at USD 417.06 MM
  • INVENTORY TURNOVER RATIO(HY) Lowest at 1.12%
2

Risky - Not traded in last 10 days

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 381 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

84.25%

stock-summary
Debt Equity

-1.62

stock-summary
Return on Equity

109.95%

stock-summary
Price to Book

-2.34

Revenue and Profits:
Net Sales:
60 Million
(Quarterly Results - Sep 2024)
Net Profit:
-38 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.85%
0%
-36.85%
6 Months
29.43%
0%
29.43%
1 Year
-32.16%
0%
-32.16%
2 Years
-89.46%
0%
-89.46%
3 Years
-73.14%
0%
-73.14%
4 Years
-87.25%
0%
-87.25%
5 Years
-86.28%
0%
-86.28%

Revance Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
201.03%
EBIT Growth (5y)
-1.22%
EBIT to Interest (avg)
-18.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.62
Sales to Capital Employed (avg)
0.54
Tax Ratio
0.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.34
EV to EBIT
-3.88
EV to EBITDA
-4.03
EV to Capital Employed
6.40
EV to Sales
2.61
PEG Ratio
NA
Dividend Yield
84.25%
ROCE (Latest)
-164.63%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 68 Schemes (46.97%)

Foreign Institutions

Held by 109 Foreign Institutions (28.78%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 5.46% vs 95.86% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 73.02% vs -66.71% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "59.90",
          "val2": "56.80",
          "chgp": "5.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.00",
          "val2": "-42.00",
          "chgp": "26.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.70",
          "val2": "5.10",
          "chgp": "31.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-95.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.10",
          "val2": "-141.20",
          "chgp": "73.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-538.70%",
          "val2": "-776.50%",
          "chgp": "23.78%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 76.47% vs 70.44% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 9.09% vs -26.70% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "234.00",
          "val2": "132.60",
          "chgp": "76.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-207.00",
          "val2": "-238.40",
          "chgp": "13.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "19.40",
          "val2": "16.50",
          "chgp": "17.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-96.10",
          "val2": "-70.80",
          "chgp": "-35.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-324.00",
          "val2": "-356.40",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-943.10%",
          "val2": "-2,053.10%",
          "chgp": "111.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoYstock-summary
Sep'24
Sep'23
Change(%)
Net Sales
59.90
56.80
5.46%
Operating Profit (PBDIT) excl Other Income
-31.00
-42.00
26.19%
Interest
6.70
5.10
31.37%
Exceptional Items
0.00
-95.20
100.00%
Consolidate Net Profit
-38.10
-141.20
73.02%
Operating Profit Margin (Excl OI)
-538.70%
-776.50%
23.78%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2024 is 5.46% vs 95.86% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is 73.02% vs -66.71% in Sep 2023

Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
234.00
132.60
76.47%
Operating Profit (PBDIT) excl Other Income
-207.00
-238.40
13.17%
Interest
19.40
16.50
17.58%
Exceptional Items
-96.10
-70.80
-35.73%
Consolidate Net Profit
-324.00
-356.40
9.09%
Operating Profit Margin (Excl OI)
-943.10%
-2,053.10%
111.00%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 76.47% vs 70.44% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 9.09% vs -26.70% in Dec 2022

stock-summaryCompany CV
About Revance Therapeutics, Inc. stock-summary
stock-summary
Revance Therapeutics, Inc.
Pharmaceuticals: Major
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.
Company Coordinates stock-summary
Company Details
1222 Demonbreun Street, Suite 1001 , NASHVILLE TN : 37203
stock-summary
Tel: 1 510 74234001 714 3253584
stock-summary
Registrar Details